Comparison of add-on treatment with Aliskiren versus Diuretics to angiotensin II receptor blocker based Therapy

Comparison of add-on treatment with Aliskiren versus Diuretics to angiotensin II receptor blocker based Therapy - Aliskiren Evaluation on Augmentation Index (ALEA) study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005726

Enrollment

140

Registered

2012-06-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Direct renin inhibitor Diuretic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, From age 30 years old to 85 years old and sex is not asked 2, The patients with SBP 140mmHg or more or DBP 90mmHg or more though it is treatment by the valsartan 80mg ,angiotensin II receptor blocker (ARB).

Exclusion criteria

Exclusion criteria: 1, Secondary hypertension 2, Severe hypertension(SBP 200mmHg or more or DBP 115mmHg or more) 3, Congestive heart failure 4, Severe valvular disease 5, Myocardial infarction or acute period of cerebrovascular disease(within 6 months) 6, Atrial fibrillation(paroxysmal,stained,chronic) 7, Malignant ventricular arrhythmia 8, Renal insufficiency(Serum creatinine 2mg/dL or more) 9, Severe Liver Dysfunction 10, Chronic inflammatory disease 11, The patient with a malignant tumor 12, Patients who are determined by the investigators to be unsuitable

Design outcomes

Primary

Measure	Time frame
Change in AI, Center blood pressure, SBP2 after 24 weeks	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Cardiovascular Medicine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026